IQAI.L

IQ-AI Limited
IQ-AI Limited - New Patent Application and Trading Update
5th November 2024, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 8681K
IQ-AI Limited
05 November 2024
 

November 5, 2024

IQ-AI Ltd

("IQ-AI" or the "Company")

 

New Patent Application, Trading Update and

Commencement of discussions with potential phase 2 partners

 

IQ-AI (LSE: IQAI) Imaging Biometrics ("IB") has filed a provisional patent application with the United States Patent and Trademark Office ("USPTO") "Gallium Maltolate (GaM) as a Cancer Treatment Agent and Method". Provisional patents are routinely used to secure an early filing date while an invention is being developed and refined. 

The Company is also pleased to report that the growth in IQ-AI's revenues, first reported at the time of our Interim Report in August, has continued. The Board now expects that total revenue for the current year will thus be between U$900,000 and U$1million. This expected material year-on-year sales increase (up from U$760,000 in 2023), has primarily been driven by sales of our software solutions.

As we have previously advised, the phase 1 clinical trial is nearing its conclusion. We have now commenced discussions with potential partners to provide funding for a phase 2 trial.

"We are extremely pleased with the revenue performance this year," said Trevor Brown, CEO of IQ-AI. "and we remain hopeful that revenue will continue to build as software innovations come on stream. Regarding IB003, the planning for a phase 2 trial will move to the centre of our attention which includes discussions with potential funding partners."

--ENDS-

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

For further information, please contact:

 

IQ-AI Ltd

Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Tel: 020 7220 9797

About Imaging Biometrics® LLC:  IB is a wholly owned subsidiary of IQ-AI Limited, (LON: IQAI), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com. Follow IB on Twitter, @IQAI_IB.  

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDEZLFBZFLFFBQ]]>
TwitterFacebookLinkedIn